¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)
¼¶±ð: ×ܰæÖ÷
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-01-25   

Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)

Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ iN bIp"W  
/j #n  
£¨ÃâÒßѧרҵºÍרҵ»ù´¡£© GSoX<*i  
GA$V0YQX  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© W,K;6TZhh  
_zR+i]9   
1.Co-stimulators (or co-stimulating molecules) K?6jXJseb  
!44/sr'  
2.NK-kB 8EZ$g< }  
+jAGGv^)  
3.Immunoglobulin superfamily +KF^Z$I  
Sgeh %f  
4.antigen-presenting cell (APC) NpE*fR')  
aHV;N#Lx3  
5.death domain +>8'mf  
0.\/\V:H6  
6.CCR and CXCR cutuDZ  
+! ]zA4x  
7.Lectin (or mitogen) iJ ($YvF4  
a[>/h3  
8.Clusters of differentiation, CD) oTEL?hw5  
O\ GEay2  
9.B7 family ?U%qPv:  
B?OFe'*  
10.Cytotoxic T lymphocyte, CTL) Z]A{ d[  
!eGC6o}f  
11.IL-15 and IL-15 receptor (IL-15R) sv2A-Dld  
_F4Ii-6  
12.MHC restriction vt/x ,Y  
a]$1D!Anc  
13.Affinity-chromatography Ja|5 @  
Rm2yPuOU}A  
14.Cyctosprin A, CsA I )~GZ  
P:hBt\5B  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) {yB s7[Wn  
6{@w="VT  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© a H yx_B  
t^UxR@l<K|  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 ^8]NxV@l  
9d>-MX '  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ ,A9]CQ  
=R^%(Py  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ zU,9T  
SDC4L <!  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© _H9 MwJ  
> ;jZa  
ÃâÒßѧרҵ£º biLs+\C  
.14~J6  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ 2kqup)82e  
>|J`s~?  
Ïû»¯ÄÚ¿Æ£º :v YYfs&  
{Je[ZQ$  
2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ xv46r=>  
+[Dx ?XM  
ѪҺ²¡Ñ§×¨Òµ£º Y`KqEjsC*  
Dxtp2wu%t  
3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
Ãâ·Ñ¿¼²©ÍøÍøÖ·ÊÇʲô? ÕýÈ·´ð°¸:freekaobo.com
°´"Ctrl+Enter"Ö±½ÓÌá½»